Agile Therapeutics Provides Regulatory Update on Twirla for the Prevention of Pregnancy
Agile Therapeutics (Nasdaq:AGRX), a women’s healthcare company, today announced the content of the official minutes from its Type A meeting...
“We’re Financially Prudent,” Says CFO and President of Knight Therapeutics Samira Sakhia
At the Bloom Burton & Co. Healthcare Investment Conference held in Toronto from May 2-3, the Investing News Network had...
Antibe Therapeutics Looking for More Licensing Deals
Antibe Therapeutics is trying to change the game of non-steroidal anti-inflammatory drugs (NSAID)—the “largest category of drugs globally,” CEO Dan...
Rocket Pharmaceuticals Announces Strategic Research Collaboration
Rocket Pharmaceuticals (NASDAQ: RCKT) a leading U.S.-based multi-platform gene therapy company, and the Stanford University School of Medicine today announced a...
LYRICA (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint
Pfizer (NYSE: PFE) announced today positive top-line results of a Phase 3 study examining the use of LYRICA® (pregabalin) Oral Solution...
BioDelivery Sciences Announces Pricing of $50 Million Equity Financing
BioDelivery Sciences International (NASDAQ:BDSI) announced that it has entered into definitive agreements with existing institutional and other accredited investors to...
New CEO and President of Acerus Shares Company’s Future Plans
At the Bloom Burton & Co. Healthcare Investor Conference which took place in Toronto from May 2-3, the Investing News...
Theratechnologies Provides Update on Trogarzo (Ibalizumab-Uiyk) Injection Prescriptions and Reimbursement Status
Theratechnologies (TSX:TH) today disclosed, during its annual meeting, information on the number of scripts and reimbursement coverage for Trogarzo™ in...
ADMA Biologics Granted U.S. Patent for Treating Respiratory Infections
ADMA Biologics (NASDAQ:ADMA) announced that the United States Patent and Trademark Office issued to the Company U.S. Patent No. 9,969,793...
Insmed Announces FDA Acceptance for Filing of New Drug Application for ALIS in NTM Lung Disease Caused by MAC
Insmed (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced today that the U.S....
